Showing 1 - 9 of 9
-patent pharmaceuticals, replacing the existing price cap (PC) regulation. We estimate the effect of the reform using a product level panel …
Persistent link: https://www.econbiz.de/10005406112
firms providing horizontally differentiated (branded) drugs. Patients differ in their susceptibility to the drugs. If DTCA … is allowed, this can be employed to induce (additional) patient visits. Physicians perfectly observe the patients' type …
Persistent link: https://www.econbiz.de/10005406241
distorts drug choices most, exposing patients to higher health risks. …
Persistent link: https://www.econbiz.de/10005406396
TNF-alpha inhibitors represent one of the most important areas of biopharmaceuticals by sales, with three blockbusters accounting for 8 per cent of total pharmaceutical sale in Norway. Novelty of the paper is to examine, with the use of a unique natural policy experiment in Norway, to what...
Persistent link: https://www.econbiz.de/10009371358
are price responsive, and that the price response is considerably higher when the doctor’s affiliated hospital covers the …
Persistent link: https://www.econbiz.de/10008727300
-savings, and that patients’ copayments decrease despite the extra surcharges under RP. …
Persistent link: https://www.econbiz.de/10008799730
construct a theoretical model where pharmacies can persuade patients with a brand-name prescription to purchase a generic … generics and their market shares. This relationship is stronger for pharmaceuticals under reference pricing rather than …
Persistent link: https://www.econbiz.de/10010603857
In the European Union, medicines are regulated products subject to both single market (e.g., regional exhaustion of property rights) and country specific health care regulations (e.g., medicines pricing and distribution regulation). This gives rise to parallel trade (PT), a phenomenon that takes...
Persistent link: https://www.econbiz.de/10011274346
death), hospital utilization, and medical expenditure in Greece during the period 1995-2010. The estimates indicate that … the number of hospital days. Real per capita pharmaceutical expenditure increased rapidly during this period, but 62% of … the increase in pharmaceutical expenditure was offset by a reduction in hospital expenditure attributable to …
Persistent link: https://www.econbiz.de/10011122677